DAA 1097 | 220551-79-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: DAA 1097
• 英文别名: N-(4-chloro-2-phenoxyphenyl)-N-(2-isopropoxylbenzyl)acetamide；[11C]-DAA 1097；N-(4-chloro-2-phenoxyphenyl)-N-(2-isopropoxybenzyl)acetamide；N-(4-chloro-2-phenoxyphenyl)-N-[(2-propan-2-yloxyphenyl)methyl]acetamide
• CAS: 220551-79-1
• 化学式: C₂₄H₂₄ClNO₃
• 分子量: 409.912
• InChiKey: CGUBOFYHGYNUDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-chloro-1-nitro-2-phenoxybenzene 在 铁粉 、 sodium hydride 、 氯化铵 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 DAA 1097
  参考文献：
  名称：

  Design, synthesis and structure–affinity relationships of aryloxyanilide derivatives as novel peripheral benzodiazepine receptor ligands

  摘要：

  Since the peripheral benzodiazepine receptor (PBR) has been primarily found as a high-affinity binding site for diazepam in rat kidney, numerous studies of it have been performed. However, the physiological role and functions of PBR have not been fully elucidated. Currently, we presented the pharmacological profile of two high and selective PBR ligands, N-(2,5-dimethoxybenzyl)-N-(4-fluoro-2-phenoxyphenyl)acetamide (7-096, DAA1106) (PBR: IC50 = 0.28 nM) and N-(4-chloro-2-phenoxyphenyl)-N-(2-isopropoxybenzyl)acetamide (7-099, DAA1097) (PBR: IC50=0.92 nM). The compounds are aryloxyanilide derivatives, and identified with known PBR ligands such as benzodiazepine (1, Ro5-4864), isoquinoline (2, PK11195), imidazopyridine (3, Alpidem), and indole (5, FGIN-1-27) derivatives. The aryloxyanilide derivatives, which have been derived by opening the diazepine ring of 1, are a novel class as PBR ligands and have exhibited high and selective affinity for peripheral benzodiazepine receptors (PBRs). These novel derivatives would be useful for exploring the functions of PBR. In this paper, the design, synthesis and structure-affinity relationships of aryloxyanilide derivatives are described. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.10.050

文献信息

• AGENTS FOR THERAPY EFFICACY MONITORING AND DEEP TISSUE IMAGING
  申请人：Bornhop J. Darryl

  公开号：US20080031823A1

  公开（公告）日：2008-02-07

  Compounds and methods related to NIR molecular imaging, in-vitro and in-vivo functional imaging, therapy/efficacy monitoring, and cancer and metastatic activity imaging. Compounds and methods demonstrated pertain to the field of peripheral benzodiazepine receptor imaging, metabolic imaging, cellular respiration imaging, cellular proliferation imaging as targeted agents that incorporate signaling agents.

  与近红外分子成像、体外和体内功能成像、治疗/疗效监测以及癌症和转移活动成像相关的化合物和方法。展示的化合物和方法涉及外周苯二氮平受体成像、代谢成像、细胞呼吸成像、细胞增殖成像作为包含信号剂的靶向剂。
• Methods for identifying peripheral benzodiazepine receptor binding agents
  申请人：——

  公开号：US20020039746A1

  公开（公告）日：2002-04-04

  The invention provides methods for screening for agents that modulate mitochondrial membrane potential. Such agents generally bind to a peripheral benzodiazepine receptor and may be detected by direct binding assays or by indirect or functional assays. Agents identified using the screens provided herein have application in the prevention and treatment of a variety of diseases associated with abnormal mitochondrial function.

  本发明提供了筛选调节线粒体膜电位的制剂的方法。此类制剂通常与外周苯并二氮杂卓受体结合，可通过直接结合试验或间接或功能试验进行检测。利用本文提供的筛选方法鉴定出的制剂可用于预防和治疗与线粒体功能异常有关的各种疾病。
• IDENTIFICATION OF PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS
  申请人：MITOKOR

  公开号：EP1250597A2

  公开（公告）日：2002-10-23
• 18F-Labeled Daa Analogues and Method of Labeling These Analogues as Positron Emission Tomography (Pet) Tracers For Imaging Peripheral Benzodiazepine Receptors
  申请人：Karimi Farhad

  公开号：US20080293969A1

  公开（公告）日：2008-11-27

  Methods for selecting novel DAA analogues for a peripheral type benzodiazepine receptor were labeled with 18 F using one-step syntheses are provided. Analogues labeled with the 18 F using the one-step synthesis method are also provided. Additionally, the purification of the Br, I, Cl, TsO, MsO, or R f SO 3 precursors in the compound of formula (II) by solid phase extraction is provided as is the precursor compounds of formula (II). A kit claim for comprising an effective amount of an 18 F labeled compound, and pharmaceutically acceptable salts and solvates thereof are also provided.
• 18F-Labeled Phenoxyphenyl Nu-benzyl Alkanamid Derivatives for Positron Emission Tomography (PET) Imaging of Peripheral Benzodiazepine Receptor
  申请人：Langstrom Bengt

  公开号：US20090142264A1

  公开（公告）日：2009-06-04

  The present invention provides novel 18 F-labeled phenoxyphenyl N-benzyl alkanamid derivative compounds that are suitable for use as an in vivo imaging agent. A pharmaceutical comprising the compound and a kit for the preparation of the pharmaceutical are also provided. Methods of use and use of claims for novel 18 F-labeled phenoxyphenyl N-benzyl alkanamid derivative compounds are provided as well.